Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Boston Partners

Boston Partners cut its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 28.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 407,984 shares of the biopharmaceutical company’s stock after selling 163,963 shares during the quarter. Boston Partners’ holdings in Halozyme Therapeutics were worth $19,955,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of HALO. Heck Capital Advisors LLC acquired a new stake in Halozyme Therapeutics during the 4th quarter valued at $29,000. CBIZ Investment Advisory Services LLC acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at $29,000. Smartleaf Asset Management LLC increased its position in Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 197 shares in the last quarter. Venturi Wealth Management LLC acquired a new position in Halozyme Therapeutics in the 4th quarter valued at about $69,000. Finally, Parkside Financial Bank & Trust lifted its holdings in Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 322 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Up 0.0 %

Shares of NASDAQ:HALO opened at $64.32 on Friday. Halozyme Therapeutics, Inc. has a 1 year low of $37.73 and a 1 year high of $65.53. The stock has a 50-day simple moving average of $57.95 and a 200-day simple moving average of $54.75. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The stock has a market capitalization of $7.92 billion, a P/E ratio of 18.75, a PEG ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.02. The company had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. Equities analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the sale, the director now owns 38,611 shares of the company’s stock, valued at $2,173,799.30. This trade represents a 11.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total transaction of $580,500.00. Following the transaction, the senior vice president now directly owns 185,453 shares in the company, valued at approximately $10,765,546.65. The trade was a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 31,697 shares of company stock valued at $1,754,451 over the last three months. 2.40% of the stock is owned by company insiders.

Analysts Set New Price Targets

HALO has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Benchmark reissued a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company dropped their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Finally, Piper Sandler raised their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $62.78.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.